Reports
EMA’s Richardson talks about biosimilars in Europe
Biosimilars have been available in Europe for more than seven years. In the US, however, despite legislation being passed in 2010 to allow for a biosimilars pathway, a biosimilar has yet to be approved [1]. EMA Head of Biologicals Dr Peter Richardson speaks to BioCentury about a new report published by the European Commission (EC) and about biosimilars in Europe in general.
The best selling biotechnology drugs of 2008: the next biosimilars targets
Last updated: 20 September 2013
According to the report Market-Leading Biotechnology Drugs 2009: Blockbuster Dynamics in an Ailing Economy, sales of the top 10 biotech drugs exceeded US$41.5 billion (Euros 28.6 billion) in 2008.
Amgen, Hospira and Sandoz set to dominate US biosimilars market
A new report released by Thomson Reuters on 14 May 2013 identifies Amgen, Hospira and Sandoz as having the greatest potential to dominate the early stages of the biosimilars market in the US.
US places India on IP black list
The US has placed India on a special trade black list of countries that have raised concerns about intellectual property rights.
Use of biosimilars in Europe
Uptake of biosimilars in Europe is slowly increasing, according to a new report published by the European Commission’s (EC) Enterprise and Industry Directorate-General.
EU publishes consensus report on biosimilars
The European Commission’s (EC’s) Enterprise and Industry Directorate-General has published a new report providing comprehensive information on the concept of biosimilars.
More UK patients affected by drug shortages in 2012
The number of UK patients affected by shortages in brand-name medicines has increased during 2012, according to an online survey carried out by pharmacists’ organization Chemist+Druggist (C+D).
Patients in US turn to generics to save money
According to a new report released on 9 April 2013 by the US Centers for Disease Control and Prevention, adults in the US used several strategies to reduce the costs of their medications, including asking their doctor for a lower-cost (generic) medicine.
Huge differences in prescription drug prices in Ireland
A survey carried out by Ireland’s National Consumer Agency (NCA) has found that the price of many commonly prescribed medicines varies widely across Ireland.
Fewer generics approved in the US during 2012
FDA approved fewer generics for the US market during 2012 than in 2011, according to a new report from Thomson Reuters.
